Show simple item record

dc.contributor.authorFish, Rebecca
dc.contributor.authorSelvasekar, Chelliah
dc.contributor.authorCrichton, Peter
dc.contributor.authorWilson, Malcolm S
dc.contributor.authorFulford, Paul E
dc.contributor.authorRenehan, Andrew G
dc.contributor.authorO'Dwyer, Sarah T
dc.date.accessioned2013-10-30T09:49:14Z
dc.date.available2013-10-30T09:49:14Z
dc.date.issued2013-09-06
dc.identifier.citationRisk-reducing laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for low-grade appendiceal mucinous neoplasm: early outcomes and technique. 2013: Surg Endoscen
dc.identifier.issn1432-2218
dc.identifier.pmid24061624
dc.identifier.doi10.1007/s00464-013-3189-8
dc.identifier.urihttp://hdl.handle.net/10541/304736
dc.description.abstractLow-grade appendiceal mucinous neoplasm (LAMN) is a precursor lesion of pseudomyxoma peritonei, which, if treated suboptimally, may later disseminate throughout the abdominal cavity. We previously demonstrated the role of cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) to reduce the dissemination risk. Here we describe the feasibility and safety of minimal access cytoreductive surgery (MACRS) and HIPEC as an alternative to the open approach.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Surgical endoscopyen
dc.titleRisk-reducing laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for low-grade appendiceal mucinous neoplasm: early outcomes and technique.en
dc.typeArticleen
dc.contributor.departmentPeritoneal Tumour Service, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK.en
dc.identifier.journalSurgical Endoscopyen
html.description.abstractLow-grade appendiceal mucinous neoplasm (LAMN) is a precursor lesion of pseudomyxoma peritonei, which, if treated suboptimally, may later disseminate throughout the abdominal cavity. We previously demonstrated the role of cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) to reduce the dissemination risk. Here we describe the feasibility and safety of minimal access cytoreductive surgery (MACRS) and HIPEC as an alternative to the open approach.


This item appears in the following Collection(s)

Show simple item record